In addition to its 20% acetylcysteine solution products, Fresenius Kabi is now offering 4 ml, 10 ml, and 30 ml vials of acetylcysteine 10% for oral use or inhalation in the US. Acetylcysteine is a mucolytic used to thin mucous in the lungs of patients with conditions such as cystic fibrosis, bronchiectasis, and pneumonia. The drug was on the FDA’s drug shortage list from as early as 2011 until February 2014.
The company launched 4 ml vials of acetylcysteine 20% in February 2014 and also sells 10 ml and 30 ml vials of the 20% solution.
Fresenius Kabi USA President and CEO John Ducker commented, “Since 2008, Fresenius Kabi has responded multiple times and in a variety of ways to meet clinician and patient needs due to US drug shortages. The introduction of acetylcysteine 10% is another example of our commitment to provide needed products in convenient presentations.”
Read the Fresenius Kabi press release.
